FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 436 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Fructose Fuels Cancer Growth Indirectly, Lab Study Finds January 14, 2025 When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic... January 23, 2023 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 Spending Review 2020 – Steps in the right direction, but opportunities... November 25, 2020 Load more HOT NEWS Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... Accepting Help During Cancer Is Hard, But It Can Benefit You... New Treatment Helps Survivors Regain Sensation After Breast Cancer
